EUVIMEDEUVIMED entdecken
Crossref

Charge variants of proposed biosimilar to Omalizumab: Isolation, purification and analysis by HPLC methods

Tarun Gupta, Sriram Seshadri

Annales Pharmaceutiques Françaises · 2024

DOI: 10.1016/j.pharma.2023.09.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annales Pharmaceutiques Françaises, 2024. Verfasst von Tarun Gupta und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Science, Nirma University, 382481 Ahmedabad, Gujarat, India; Downstream Process Development, Kashiv BioSciences Pvt Ltd., 382210 Ahmedab…. Hauptthemen laut MEDLINE: Omalizumab, Biosimilar Pharmaceuticals. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Nirma University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Omalizumab (Xolair) is a humanized monoclonal antibody derived by recombinant DNA technology. It binds specifically to immunoglobulin E (IgE) which plays a major role in allergic reaction by releasing histamine and other inflammatory factors from mast cells. Omalizumab binds circulatory IgE with high affinity and prevents from its binding to mast cell receptor. Charge variants are one of the critical quality attributes (CQAs) in biological drug development and sources of heterogeneity which needs to be considered in biosimilarity assessment. In this study, biosimilar product of Xolair was expressed in mammalian cell culture process in laboratory to isolate charge variants (acidic, main peak and basic). Different charge variants were isolated from intermediate purified biosimilar product of Xolair. Isolated charge variants were purified with preparative cation exchange chromatography technique and characterized with different analytical tools includes size exclusion chromatography (SEC-HPLC) and cation exchange chromatography (CEX-HPLC). Purity of acidic, main peak and basic variants was 99.58%, 99.98% and 98.64% respectively as per SEC-HPLC and according to CEX-HPLC purity was 94.25%, 95.58% and 91.33% respectively. The study data indicates that isolated charge variants were purified with desired purity and can be further used for process characterization, in vitro potency and in vivo kinetics studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabBiosimilar PharmaceuticalsAnimalsChromatography, High Pressure LiquidImmunoglobulin ECationsMammals

Stichwörter der Autor:innen

ChromatographieChromatographyDes anticorps monoclonauxImmunoglobulin EImmunoglobuline EMonoclonal antibodiesPotencyPuissanceXolair

Substanzen

OmalizumabBiosimilar PharmaceuticalsImmunoglobulin ECations

Autor:innen und Institutionen

  • Institute of Science, Nirma University, 382481 Ahmedabad, Gujarat, India; Downstream Process Development, Kashiv BioSciences Pvt Ltd., 382210 Ahmedabad, Gujarat, India.
  • Institute of Science, Nirma University, 382481 Ahmedabad, Gujarat, India. Electronic address: sriram.seshadri@nirmauni.ac.in.

Förderung

  • Nirma University

Zitieren

APA

Gupta, T., & Seshadri, S. (2024). Charge variants of proposed biosimilar to Omalizumab: Isolation, purification and analysis by HPLC methods. Annales Pharmaceutiques Françaises. https://doi.org/10.1016/j.pharma.2023.09.003

Vancouver

Gupta T, Seshadri S. Charge variants of proposed biosimilar to Omalizumab: Isolation, purification and analysis by HPLC methods. Annales Pharmaceutiques Françaises. 2024. doi:10.1016/j.pharma.2023.09.003

BibTeX
@article{Gupta2024,
  author = {Gupta, Tarun and Seshadri, Sriram},
  title = {Charge variants of proposed biosimilar to Omalizumab: Isolation, purification and analysis by HPLC methods},
  journal = {Annales Pharmaceutiques Françaises},
  year = {2024},
  doi = {10.1016/j.pharma.2023.09.003}
}
Kostenlos starten →